For research use only. Not for therapeutic Use.
SG2057（Cat No.:I008856）is a small molecule compound under investigation for its potential therapeutic applications in cancer treatment. It functions as a selective inhibitor of certain kinases involved in cellular processes such as proliferation, survival, and apoptosis. By targeting these kinases, SG2057 may disrupt cancer cell growth and survival, offering a promising strategy for treating various cancers. Research is focused on evaluating its efficacy and safety in preclinical and clinical studies, particularly in tumors that are resistant to conventional therapies. SG2057 holds potential as part of targeted cancer therapy regimens.
| CAS Number | 260417-62-7 |
| Synonyms | (6aS)-3-[5-[[(6aS)-2-methoxy-8-methylidene-11-oxo-7,9-dihydro-6aH-pyrrolo[2,1-c][1,4]benzodiazepin-3-yl]oxy]pentoxy]-2-methoxy-8-methylidene-7,9-dihydro-6aH-pyrrolo[2,1-c][1,4]benzodiazepin-11-one |
| Molecular Formula | C33H36N4O6 |
| Purity | ≥95% |
| IUPAC Name | (6aS)-3-[5-[[(6aS)-2-methoxy-8-methylidene-11-oxo-7,9-dihydro-6aH-pyrrolo[2,1-c][1,4]benzodiazepin-3-yl]oxy]pentoxy]-2-methoxy-8-methylidene-7,9-dihydro-6aH-pyrrolo[2,1-c][1,4]benzodiazepin-11-one |
| InChI | InChI=1S/C33H36N4O6/c1-20-10-22-16-34-26-14-30(28(40-3)12-24(26)32(38)36(22)18-20)42-8-6-5-7-9-43-31-15-27-25(13-29(31)41-4)33(39)37-19-21(2)11-23(37)17-35-27/h12-17,22-23H,1-2,5-11,18-19H2,3-4H3/t22-,23-/m0/s1 |
| InChIKey | KYNCKSRRIFFPJS-GOTSBHOMSA-N |
| SMILES | COC1=C(C=C2C(=C1)C(=O)N3CC(=C)C[C@H]3C=N2)OCCCCCOC4=C(C=C5C(=C4)N=C[C@@H]6CC(=C)CN6C5=O)OC |
